当前位置：
X-MOL 学术
›
Cent. Eur. J. Immunol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Efficacy of IL-23 inhibitors and IL-12/23 inhibitors in the induction treatment of Crohn’s disease: A meta-analysis based on randomized controlled trials
Central European Journal of Immunology ( IF 1.3 ) Pub Date : 2024-01-09 , DOI: 10.5114/ceji.2023.134257 Boyang Gao , Haojie Shentu , Suyong Sha , Dongying Wang , Xi Chen , Zhenwei Huang , Nan Dong , Haijia Lai , Jianying Xu , Xiaoshuai Zhou
Central European Journal of Immunology ( IF 1.3 ) Pub Date : 2024-01-09 , DOI: 10.5114/ceji.2023.134257 Boyang Gao , Haojie Shentu , Suyong Sha , Dongying Wang , Xi Chen , Zhenwei Huang , Nan Dong , Haijia Lai , Jianying Xu , Xiaoshuai Zhou
Introduction:
A growing number of randomized controlled trials (RCTs) have demonstrated the effectiveness of interleukin (IL)-23 and IL-12/23 inhibitors in treating Crohn’s disease (CD). This study evaluated the efficacy of IL-23 and IL-12/23 inhibitors in the induction phase for the treatment of CD.
Material and methods:
We searched the following databases from inception until December, 2022: Medline, Embase, Web of Science and the Cochrane Library. The primary outcome was the proportion of CD patients who achieved clinical remission at the end of the induction therapy period. Secondary outcomes included clinical response, endoscopic remission, endoscopic response and normalized C-reactive protein (CRP).
Results:
After screening, 7 RCTs were included in our study. The meta-analysis showed that, in the induction period, more patients treated with IL-23 inhibitors and IL-12/23 inhibitors achieved clinical remission than patients with placebo therapy (RR = 2.11, 95% CI: 1.83-2.44; RR = 1.94, 95% CI: 1.64-2.29; respectively). The IL-23 inhibitor group and the IL-12/23 inhibitor group showed higher clinical response rates than the placebo group (RR = 1.92, 95% CI: 1.74-2,11; RR = 1.83, 95% CI: 1.61-2.09; respectively). In addition, the IL-23 inhibitor group had a higher endoscopic remission rate and endoscopic response rate than the placebo group; the corresponding pooled RRs were 3.40 (95% CI:2.57-4.50) and 2.65 (95% CI: 2.65-3.12), respectively.
Conclusions:
IL-23 and IL-12/23 inhibitors were efficient methods in the induction treatment of CD.
中文翻译：
IL-23抑制剂和IL-12/23抑制剂在克罗恩病诱导治疗中的疗效：基于随机对照试验的荟萃分析
简介：
越来越多的随机对照试验 (RCT) 已证明白细胞介素 (IL)-23 和 IL-12/23 抑制剂在治疗克罗恩病 (CD) 方面的有效性。本研究评估了 IL-23 和 IL-12/23 抑制剂在诱导期治疗 CD 的疗效。
材料和方法：
我们从成立到 2022 年 12 月检索了以下数据库：Medline、Embase、Web of Science 和 Cochrane Library。主要结局是在诱导治疗期结束时获得临床缓解的 CD 患者的比例。次要结局包括临床反应、内镜缓解、内镜反应和标准化 C 反应蛋白 (CRP)。
结果：
经过筛选，7 项 RCT 纳入我们的研究。荟萃分析显示，在诱导期，接受IL-23抑制剂和IL-12/23抑制剂治疗的患者比接受安慰剂治疗的患者有更多的患者获得临床缓解（RR = 2.11，95% CI：1.83-2.44；RR = 1.94，95% CI：1.64-2.29；分别）。IL-23抑制剂组和IL-12/23抑制剂组的临床缓解率高于安慰剂组（RR = 1.92，95% CI：1.74-2,11；RR = 1.83，95% CI：1.61-2.09） ; 分别）。此外，IL-23抑制剂组的内镜缓解率和内镜缓解率均高于安慰剂组；相应的合并 RR 分别为 3.40 (95% CI:2.57-4.50) 和 2.65 (95% CI: 2.65-3.12)。
结论：
IL-23和IL-12/23抑制剂是诱导治疗CD的有效方法。
更新日期：2024-01-09
A growing number of randomized controlled trials (RCTs) have demonstrated the effectiveness of interleukin (IL)-23 and IL-12/23 inhibitors in treating Crohn’s disease (CD). This study evaluated the efficacy of IL-23 and IL-12/23 inhibitors in the induction phase for the treatment of CD.
Material and methods:
We searched the following databases from inception until December, 2022: Medline, Embase, Web of Science and the Cochrane Library. The primary outcome was the proportion of CD patients who achieved clinical remission at the end of the induction therapy period. Secondary outcomes included clinical response, endoscopic remission, endoscopic response and normalized C-reactive protein (CRP).
Results:
After screening, 7 RCTs were included in our study. The meta-analysis showed that, in the induction period, more patients treated with IL-23 inhibitors and IL-12/23 inhibitors achieved clinical remission than patients with placebo therapy (RR = 2.11, 95% CI: 1.83-2.44; RR = 1.94, 95% CI: 1.64-2.29; respectively). The IL-23 inhibitor group and the IL-12/23 inhibitor group showed higher clinical response rates than the placebo group (RR = 1.92, 95% CI: 1.74-2,11; RR = 1.83, 95% CI: 1.61-2.09; respectively). In addition, the IL-23 inhibitor group had a higher endoscopic remission rate and endoscopic response rate than the placebo group; the corresponding pooled RRs were 3.40 (95% CI:2.57-4.50) and 2.65 (95% CI: 2.65-3.12), respectively.
Conclusions:
IL-23 and IL-12/23 inhibitors were efficient methods in the induction treatment of CD.
中文翻译：
IL-23抑制剂和IL-12/23抑制剂在克罗恩病诱导治疗中的疗效：基于随机对照试验的荟萃分析
简介：
越来越多的随机对照试验 (RCT) 已证明白细胞介素 (IL)-23 和 IL-12/23 抑制剂在治疗克罗恩病 (CD) 方面的有效性。本研究评估了 IL-23 和 IL-12/23 抑制剂在诱导期治疗 CD 的疗效。
材料和方法：
我们从成立到 2022 年 12 月检索了以下数据库：Medline、Embase、Web of Science 和 Cochrane Library。主要结局是在诱导治疗期结束时获得临床缓解的 CD 患者的比例。次要结局包括临床反应、内镜缓解、内镜反应和标准化 C 反应蛋白 (CRP)。
结果：
经过筛选，7 项 RCT 纳入我们的研究。荟萃分析显示，在诱导期，接受IL-23抑制剂和IL-12/23抑制剂治疗的患者比接受安慰剂治疗的患者有更多的患者获得临床缓解（RR = 2.11，95% CI：1.83-2.44；RR = 1.94，95% CI：1.64-2.29；分别）。IL-23抑制剂组和IL-12/23抑制剂组的临床缓解率高于安慰剂组（RR = 1.92，95% CI：1.74-2,11；RR = 1.83，95% CI：1.61-2.09） ; 分别）。此外，IL-23抑制剂组的内镜缓解率和内镜缓解率均高于安慰剂组；相应的合并 RR 分别为 3.40 (95% CI:2.57-4.50) 和 2.65 (95% CI: 2.65-3.12)。
结论：
IL-23和IL-12/23抑制剂是诱导治疗CD的有效方法。
京公网安备 11010802027423号